GSK

At A Glance

Over the last 3 years GSK, under the helm of Group CEO Emma Walmsley, has pivoted into a much more competitive model. Against a changing environment of pricing pressure, technology disruption, and consolidation, significant changes include:

Transforming the company into a world class Bio-Pharmaceutical company
Competitive launches via accelerating Pharma investment on priority countries and products to drive growth
Delayering the business in Emerging Markets & Classic and Established Products to drive better decision making and a culture of accountability and high performance for double digit growth.

I have always believed that the question of culture is fundamental for any organization. Culture – mainly defined not by the values and expectations written on the wall but by the way that leadership behaves – can be a fantastic accelerator for change, but can also be a complete derailer if a company gets it wrong. When I laid out the priorities for GSK, they were innovation, performance and trust to the power of ‘c’ for ‘culture.

Emma Walmsley

Group CEO, GSK

For some people it has been uncomfortable, and that is why updating talent is also important. Although many of the people who have come before have done incredibly important things, and in some cases been successful for a period, when you are redesigning and resetting what you want to do for the next chapter, you need to have fit-for-purpose leaders who embrace the kind of culture that you want

Emma Walmsley

Group CEO

Client Challenge

CorporateDNA was invited to partner with GSK at the peak of this major transformation as the red threads across culture, leadership and talent and high performing teams became very deliberate. Our mandate was to focus on shifting the the two large businesses:

Against this blueprint of the “Why and What” of this transformation becoming very clear, changes across GSK’s purpose, goals, strategies, priorities, values and expectations, the “How and Who” became extremely important.

CorporateDNA Solution:

Here’s how we have partnered with GSK across Europe, U.S. and Asia Pacific:

ASIA LEADERSHIP PROGRAM
HIGH PERFORMING TEAMS
MAJOR CULTURE TRANSFORMATIONS

Results

New ways of working with new mindsets, behaviours and sense of accountability established for the organization’s LT and LT -1 levels.

Increased engagement in both leadership and followership across functions and markets.

The annual GSK survey results showed significant increase in satisfaction across emerging markets.

At the end of the 9 month journey, CorporateDNA assessed the key achievements in Emerging Markets where a clear turnaround was evident. The proof points from the EM Leadership team included:

Owning the double digit ambition forecast from grassroots
Higher quality business reviews and clear direction setting
Clear alignment on purpose
Early signs of winning from gaining back market share, profit protection initiatives and increased customer engagement
Direct, productive and honest conversations with seniors that enabled alignment and collaboration
Sharper focus on the key products that matter with clear accountability through a new and agile structure
Competitive performance and understanding the importance of a smart allocation of resources

COVID-19 accelerated the pressure and urgency on our leadership teams to re-think and challenge every aspect of our business. Thanks CorporateDNA for bringing such high energy and engagement during such tough times, and for being so agile and adaptive in how you partnered with us on the transformation. Leading change this year would have been much harder without you.

At A Glance

Emma Walmsley

Group CEO, GSK

Emma Walmsley

Group CEO

Client Challenge

CorporateDNA Solution:

Results

EMLT

GSK 2020

Explore more Client Stories

HEINEKEN

Unilever

Shell

Morgan Stanley

aviva

Coca Cola

Levis

London

singapore

Dubai

Saudi Arabia

CONTACT US

Ready to change your conversations? We can help transform your teams at all layers of the organization, from Executives, Board-Level Leaders, New Talent, and more.